Evidence map›Paper›PMID 29028802›Full record

ArticlePloS one2017

Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination.

Anita H J van den Biggelaar, Peter C Richmond, Angela Fuery, Denise Anderson, Christine Opa, Gerard Saleu, Mildred Lai, Jacinta P Francis, Michael P Alpers, William S Pomat and 1 more

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00219401 phase2completednot on this map

Neonatal Immunization With Pneumococcal Conjugate Vaccine in Papua New Guinea

TypeinterventionalSponsorPapua New Guinea Institute of Medical ResearchRan2005 to 2010Enrolled318ConditionsPneumonia, Meningitis, Otitis MediaArmsPneumococcal 7 valent conjugate vaccine (Prevenar®)
NCT01414504 phase2completednot on this map

Pneumococcal Conjugate Vaccine Followup: Investigation of Serotype-specific Antibody Persistence and B Cell Memory at Age 3-5 Years Following 23valent Pneumococcal Polysaccharide Vaccine at Age 9 Months in PNG Children Previously Primed With 7valent Pneumococcal Conjugate Vaccine

TypeinterventionalSponsorWilliam PomatRan2009 to 2012Enrolled280ConditionsImmune ToleranceArmsPrevenar + PPV, Infant PCV (Prevenar) + PPV at 9 months, No Prevenar + PPV at 9 months, Control
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Anita H J van den BiggelaarTelethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia.ORCID http://orcid.org/0000-0002-3323-7261
Peter C RichmondSchool of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia.
Angela FuerySchool of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia.
Denise AndersonTelethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia.
Christine OpaPapua New Guinea Institute of Medical Research, Goroka, Eastern Highlands Province, Papua New Guinea.
Gerard SaleuPapua New Guinea Institute of Medical Research, Goroka, Eastern Highlands Province, Papua New Guinea.
Mildred LaiPapua New Guinea Institute of Medical Research, Goroka, Eastern Highlands Province, Papua New Guinea.
Jacinta P FrancisPapua New Guinea Institute of Medical Research, Goroka, Eastern Highlands Province, Papua New Guinea.
Michael P AlpersInternational Health, School of Health Sciences, Curtin University, Perth, Western Australia, Australia.
William S PomatPapua New Guinea Institute of Medical Research, Goroka, Eastern Highlands Province, Papua New Guinea.
Deborah LehmannTelethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia.
Papua New Guinea Institute of Medical Research · PGThe Kids Research Institute Australia · AUThe University of Western Australia · AUCurtin University · AU

Funding

Wellcome Trust
6 · The paper itself

Abstract

TRIAL

designIn an earlier trial, Papua New Guinean (PNG) children at high risk of pneumococcal disease were randomized to receive 0 or 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7), followed by a single dose of 23-valent pneumococcal polysaccharide vaccine (PPV23) at 9 months of age. We here studied in a non-randomized follow-up trial the persistence of pneumococcal immunity in these children at 3-5 years of age (n = 132), and in 121 community controls of a similar age with no prior pneumococcal vaccination.

methodsCirculating IgG antibody titers to all PCV7 and PPV23-only serotypes 2, 5 and 7F were measured before and after challenge with 1/5th of a normal PPV23 dose. Serotype-specific memory B-cells were enumerated at 10 months and 3-5 years of age for a subgroup of study children.

resultsSerotype-specific IgG antibody titers before and after challenge were similar for children who received PCV7/PPV23, PPV23 only, or no pneumococcal vaccines. Before challenge, at least 89% and 59% of children in all groups had serotype-specific titers ≥ 0.35μg/ml and ≥ 1.0 μg/ml, respectively. Post-challenge antibody titers were higher or similar to pre-challenge titers for most children independent of pneumococcal vaccination history. The rise in antibody titers was significantly lower when pre-challenge titers were higher. Overall the relative number of serotype-specific memory B-cells remained the same or increased between 10 months and 3-5 years of age, and there were no differences in serotype-specific memory B-cell numbers at 3-5 years of age between the three groups.

conclusionsImmunity induced by PCV7 and/or PPV23 immunization in infancy does not exceed that of naturally acquired immunity in 3-5-year-old children living in a highly endemic area. Also, there was no evidence that PPV23 immunization in the first year of life following PCV7 priming induces longer-term hypo-responsiveness.

trial registrationClinicaltrials.gov NCT01414504 and NCT00219401.

Indexed as

VaccinationAntibodies, BacterialB-LymphocytesChild, PreschoolDose-Response Relationship, RadiationFemaleHumansInfantInfant, NewbornMalePapua New GuineaPneumococcal VaccinesStreptococcus pneumoniaeVaccines, ConjugateAntibodies, BacterialPneumococcal VaccinesVaccines, Conjugate

Identifiers

PMID29028802
PMCPMC5640225
OpenAlexW2762082042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.